Method development and validation of ursodiol and its major metabolites in human plasma by HPLC-tandem mass spectrometry

Márcio Cardoso Pinto, Danilo Chorfi Berton, Alexandre Cavenatti de Oliveira, Carolina Martins Lazaro, Silvana Aparecida Calafatti Carandina Pharmacology Department (UNIFAG), Universidade São Francisco, Bragança Paulista, SP, Brazil Background: Ursodeoxycholic acid (U...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pinto MC, Chorfi Berton D, Cavenatti de Oliveira A, Lazaro CM, Aparecida Calafatti Carandina S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Ursodeoxycholic acid Glicoursodeoxycholic acid Tauroursodeoxycholic acid Bioequivalence LC-MS/MS Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/56aefa18fc7e4dd4a8910350678c2e92
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:56aefa18fc7e4dd4a8910350678c2e92
record_format	dspace
spelling	oai:doaj.org-article:56aefa18fc7e4dd4a8910350678c2e922021-12-02T00:04:08ZMethod development and validation of ursodiol and its major metabolites in human plasma by HPLC-tandem mass spectrometry1179-1438https://doaj.org/article/56aefa18fc7e4dd4a8910350678c2e922019-01-01T00:00:00Zhttps://www.dovepress.com/method-development-and-validation-of-ursodiol-and-its-major-metabolite-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Márcio Cardoso Pinto, Danilo Chorfi Berton, Alexandre Cavenatti de Oliveira, Carolina Martins Lazaro, Silvana Aparecida Calafatti Carandina Pharmacology Department (UNIFAG), Universidade São Francisco, Bragança Paulista, SP, Brazil Background: Ursodeoxycholic acid (UDCA) and its metabolites tauroursodeoxycholic acid (TUDCA) and glycoursodeoxycholic acid (GUDCA) have been the subject of several pharmacological studies. The objective of this study was to develop an innovative method of quantification by HPL-tandem mass spectrometry (LC-MS/MS), with a lower cost and suitable, for application in bioequivalence studies. Methods: The procedure involved liquid–liquid extraction for quantification of UDCA/GUDCA and precipitation extraction for TUDCA, using deuterated substances as internal standards (ISs) and Phenomenex Luna 250×4.6 mm 5μ C18 100A column. The mobile phase used was acetonitrile/ammonium acetate 30 mM (420: 580 v/v pH 7) for UDCA, acetonitrile/ammonium acetate 10 mM/ammonium hydroxide (400:600: 0.5 v/v/v pH 9) for GUDCA, and acetonitrile/ammonium acetate 10 mM (570: 430 v/v pH 7) for TUDCA. Ions were monitored by the electrospray ion source (ESI) mass spectrometer, operating in a negative ionization mode. Compound determination was performed by LC-MS/MS system using a calibration curve of 15–10,000 ng/mL for UDCA/GUDCA and 5–500 ng/mL for TUDCA. The method was developed and validated according to the Brazilian National Health Surveillance Agency (ANVISA) of Brazil norms harmonized with the main international guidelines as a prerequisite for conducting in vivo study in human volunteers. Results: The method did not present matrix effect and residual effect, showing to be selective for studied molecules, with adequate accuracy and precision. In addition, the method was considered sensitive presenting a coefficient of variation less than 20% for the lower limit of quantification of each compound.Conclusion: This method can be applied in bioequivalence studies to determine ursodiol and its metabolites reproducibly, simply, and effectively with the use of readily accessible analytical materials and instrumentation. Keywords: ursodeoxycholic acid, glicoursodeoxycholic acid, tauroursodeoxycholic acid, bioequivalence, LC-MS/MSPinto MCChorfi Berton DCavenatti de Oliveira ALazaro CMAparecida Calafatti Carandina SDove Medical PressarticleUrsodeoxycholic acidGlicoursodeoxycholic acidTauroursodeoxycholic acidBioequivalenceLC-MS/MSTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 11, Pp 1-13 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ursodeoxycholic acid Glicoursodeoxycholic acid Tauroursodeoxycholic acid Bioequivalence LC-MS/MS Therapeutics. Pharmacology RM1-950
spellingShingle	Ursodeoxycholic acid Glicoursodeoxycholic acid Tauroursodeoxycholic acid Bioequivalence LC-MS/MS Therapeutics. Pharmacology RM1-950 Pinto MC Chorfi Berton D Cavenatti de Oliveira A Lazaro CM Aparecida Calafatti Carandina S Method development and validation of ursodiol and its major metabolites in human plasma by HPLC-tandem mass spectrometry
description	Márcio Cardoso Pinto, Danilo Chorfi Berton, Alexandre Cavenatti de Oliveira, Carolina Martins Lazaro, Silvana Aparecida Calafatti Carandina Pharmacology Department (UNIFAG), Universidade São Francisco, Bragança Paulista, SP, Brazil Background: Ursodeoxycholic acid (UDCA) and its metabolites tauroursodeoxycholic acid (TUDCA) and glycoursodeoxycholic acid (GUDCA) have been the subject of several pharmacological studies. The objective of this study was to develop an innovative method of quantification by HPL-tandem mass spectrometry (LC-MS/MS), with a lower cost and suitable, for application in bioequivalence studies. Methods: The procedure involved liquid–liquid extraction for quantification of UDCA/GUDCA and precipitation extraction for TUDCA, using deuterated substances as internal standards (ISs) and Phenomenex Luna 250×4.6 mm 5μ C18 100A column. The mobile phase used was acetonitrile/ammonium acetate 30 mM (420: 580 v/v pH 7) for UDCA, acetonitrile/ammonium acetate 10 mM/ammonium hydroxide (400:600: 0.5 v/v/v pH 9) for GUDCA, and acetonitrile/ammonium acetate 10 mM (570: 430 v/v pH 7) for TUDCA. Ions were monitored by the electrospray ion source (ESI) mass spectrometer, operating in a negative ionization mode. Compound determination was performed by LC-MS/MS system using a calibration curve of 15–10,000 ng/mL for UDCA/GUDCA and 5–500 ng/mL for TUDCA. The method was developed and validated according to the Brazilian National Health Surveillance Agency (ANVISA) of Brazil norms harmonized with the main international guidelines as a prerequisite for conducting in vivo study in human volunteers. Results: The method did not present matrix effect and residual effect, showing to be selective for studied molecules, with adequate accuracy and precision. In addition, the method was considered sensitive presenting a coefficient of variation less than 20% for the lower limit of quantification of each compound.Conclusion: This method can be applied in bioequivalence studies to determine ursodiol and its metabolites reproducibly, simply, and effectively with the use of readily accessible analytical materials and instrumentation. Keywords: ursodeoxycholic acid, glicoursodeoxycholic acid, tauroursodeoxycholic acid, bioequivalence, LC-MS/MS
format	article
author	Pinto MC Chorfi Berton D Cavenatti de Oliveira A Lazaro CM Aparecida Calafatti Carandina S
author_facet	Pinto MC Chorfi Berton D Cavenatti de Oliveira A Lazaro CM Aparecida Calafatti Carandina S
author_sort	Pinto MC
title	Method development and validation of ursodiol and its major metabolites in human plasma by HPLC-tandem mass spectrometry
title_short	Method development and validation of ursodiol and its major metabolites in human plasma by HPLC-tandem mass spectrometry
title_full	Method development and validation of ursodiol and its major metabolites in human plasma by HPLC-tandem mass spectrometry
title_fullStr	Method development and validation of ursodiol and its major metabolites in human plasma by HPLC-tandem mass spectrometry
title_full_unstemmed	Method development and validation of ursodiol and its major metabolites in human plasma by HPLC-tandem mass spectrometry
title_sort	method development and validation of ursodiol and its major metabolites in human plasma by hplc-tandem mass spectrometry
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/56aefa18fc7e4dd4a8910350678c2e92
work_keys_str_mv	AT pintomc methoddevelopmentandvalidationofursodiolanditsmajormetabolitesinhumanplasmabyhplctandemmassspectrometry AT chorfibertond methoddevelopmentandvalidationofursodiolanditsmajormetabolitesinhumanplasmabyhplctandemmassspectrometry AT cavenattideoliveiraa methoddevelopmentandvalidationofursodiolanditsmajormetabolitesinhumanplasmabyhplctandemmassspectrometry AT lazarocm methoddevelopmentandvalidationofursodiolanditsmajormetabolitesinhumanplasmabyhplctandemmassspectrometry AT aparecidacalafatticarandinas methoddevelopmentandvalidationofursodiolanditsmajormetabolitesinhumanplasmabyhplctandemmassspectrometry
_version_	1718403929320980480

Method development and validation of ursodiol and its major metabolites in human plasma by HPLC-tandem mass spectrometry

Ejemplares similares